Idorsia And J&J Hypertension Drug Edges Closer To An Uncertain Market

24 May 2022

• By Ayisha Sharma

The partners released positive data from a Phase III study of their resistant hypertension drug candidate, aprocitentan, and have already started talks with regulators, but its commercial prospects remain uncertain.

The Commercial Prospects Of Aprocitentan Are Still Murky • Source: Shutterstock

Johnson & Johnson and Idorsia Pharmaceuticals Ltd’s drug candidate for resistant hypertension, aprocitentan, may have succeeded in a pivotal study sparking plans for a filing by the end of the year, but analysts remain cautious about it how well it will perform commercially.

Around 10-20% of the one billion people worldwide with hypertension have persistent high blood pressure despite taking at least three medications from different classes, including a diuretic. Idorsia estimates there could be 10 million resistant hypertension patients each in the US and EU by 2025

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

06 May 2025

• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

06 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

05 May 2025

• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.